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Abstract
α6* nicotinic acetylcholine receptors (nAChRs) are highly expressed in mesostriatal and
nigrostriatal dopaminergic systems, and participate in motor control, reward, and learning and
memory. In vitro functional expression of α6* nAChRs is essential for full pharmacological
characterization of these receptors and for drug screening, but has been challenging. We expressed
eGFP-tagged-α6 and β2 nAChR subunits in Neuro-2a cells, leading to functional channels. Inward
currents were elicited with 300 μM ACh in 26% (5/19) of cells with evenly expressed α6-eGFP in
cytoplasm and periphery. We dramatically increased chances of detecting functional α6-eGFPβ2
nAChRs by (i) introducing two endoplasmic reticulum (ER) export-enhancing mutations into β2
subunits, and (ii) choosing cells with abundant Sec24D-mCherry-labeled ER exit sites. Both
manipulations also modestly increased α6-eGFPβ2 nAChR current amplitude. α6-eGFPβ2
nAChRs were also activated by nicotine and by TC-2403. The α6-eGFPβ2 currents were
desensitized by 1 μM nicotine, blocked by α-conotoxin MII, partially inhibited by dihydro-β-
erythroidine, and potentiated by extracellular Ca2+. Single-channel recordings showed that α6-
eGFPβ2 nAChRs had similar single channel conductance to, but longer open time than, α4-
eGFPβ2 nAChRs. These methods provide avenues for developing cell lines expressing subtypes of
α6* nAChRs for both pharmacological study and drug screening.
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1. Introduction
Nicotinic acetylcholine receptors containing the α6-subunits (α6* nAChRs) are expressed in
only a few mammalian brain regions [1–8], with high expression in mesolimbic and
nigrostriatal dopaminergic systems. Current knowledge regarding α6* nAChR function and
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drug screening is based primarily on mouse models, including lines lacking α6, α4, β2, or β3
subunits, as well as lines expressing hypersensitive α6 (L9′S) subunits [2–3, 5, 7–9]. α-
conotoxin MII is an α6* nAChR antagonist[5–6]. Functional α6* nAChR responses can be
isolated by measuring α-conotoxin MII-sensitive components of nicotine- or ACh- induced
responses [2–3, 5, 9]. α6L9′S transgenic mice enable selective activation of α6* nAChRs
with low concentrations of nicotine or other nicotinic ligands which activate α6* nAChRs
[2–3].
These systems and protocols revealed that α6* nAChRs include a group of heteropentameric
subtypes, including α6α4β2β3, α6α4β2, α6β2β3, and α6β2 nAChRs [2, 5, 7]. The β2 subunit
is present in all characterized α6* nAChR combinations in dopaminergic neurons [8].
α6α4β3β2 nAChRs are the most sensitive subtype [7–8], and deleting either α4 or β3
subunits decreases receptor sensitivity [7]. α6* nAChRs participate in both motor control
and reward. For instance, 1) Knocking out α4 subunits, which decreases the sensitivity of
α6* nAChRs, eliminates behavioral hyperactivity observed in α6L9′S transgenic mice [2];
2) α6* nAChRs are lost with degeneration of nigrostriatal dopaminergic system in
Parkinson's disease [5–6, 10]; 3) Knocking out α6 subunits or blocking α6* nAChRs
prevents nicotine self-administration [11–13]. Therefore, α6* nAChRs could be promising
targets for both Parkinson's disease treatment and smoking cessation.
Progress in understanding α6* nAChR pharmacology is hindered by the fact that native
expression systems currently available cannot adequately discriminate α6* nAChR subtypes.
It is therefore important and necessary to establish robust and reproducible In vitro
heterologous methods to express specific α6* nAChR combinations for pharmacological
characterization and high-throughput drug screening.
Successful expression of functional α6* nAChRs in heterologous systems has so far been
challenging [14–19]. In In vitro expression systems, α6 subunits form mature, functional
receptors more efficiently with β4 subunits [15] than with β2 and β3 subunits [15–17, 19].
Although α6 and β2 subunits form agonist binding sites in human embryonic kidney cell
lines, only 15% of cells show detectable ACh currents [20]. Kuryatov et al constructed
chimeras replacing the extracellular domain of α3 or α4 subunit with that of α6 subunit, and
also dimeric and trimeric concatamers. These constructs do form functional α6β2β3 nAChRs
[17–18]; however, they could alter either the machinery of channel gating or high order
structures of the receptors.
In this study, we fused enhanced green fluorescent protein (eGFP) within the intracellular
M3–M4 loop of α6 subunits, and detected functional α6β2 nAChRs in 26% of Neuro-2a
cells. Introducing a recently reported β2 subunit with enhanced endoplasmic reticulum (ER)
export (β2-DM, also called β2enhanced-ER-export) [21] dramatically increased the number of
transfected cells expressing functional α6β2 nAChRs. Further, transfecting an mCherry-
tagged ER exit site (ERES) marker (Sec24D-mCherry) facilitated visualizing and choosing
cells expressing functional receptors. Studying this heterologous expression system, we
characterized pharmacological and electrophysiological properties of α6β2 nAChRs with
whole-cell and outside-out patch clamp recordings.
2. Methods and materials
2.1. Cell culture and nicotinic receptor transfection
α6-eGFP was subcloned from an α6-eYFP construct [14]. We transfected mouse α6-
eGFPβ2-wt (wild type), α6-eGFPβ2-DM, or α4-eGFPα2-wt nAChRs into Neuro-2a cells
(mouse neuroblastoma 2a, CCL-131). For transfections, sterilized 12 mm ø glass coverslips
(Deckgläser, Czech Republic, Prague) were placed in 35-mm culture dishes. Fifty thousand
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Neuro-2a cells in culture medium, composed of 45% DMEM, 45% Opti-MEM, 10% fetal
bovine serum, were plated onto coverslips and cultured in an incubator (37°C, 95% air, 5%
CO2). Twenty four hours after plating, a mixture of 4 μl Expressfect Transfection Reagent
(E2600, Denville Scientific Inc.) and appropriate plasmids were added to 0.2 ml DMEM,
and equilibrated for 20 min at room temperature. Cells were washed with DMEM twice to
remove culture medium, and incubated with 0.2 ml transfection mixture in 1 ml culture
medium for 4 hours (37°C, 95% air, 5% CO2). Cells were then washed twice with culture
medium and incubated in a final volume of 3 ml culture medium. Forty-eight hours later, the
cells were ready for electrophysiological recording or imaging. Plasmid concentrations for
transfection were as follows: 500 ng α6-eGFP and 500 ng β2-wt / β2-DM subunits, with or
without 250 ng Sec24D-mCherry. We previously reported the expression of other nAChRs
and transporters with this expression system, with regard to dependence on DNA levels,
trafficking, and surface density [21–23]. The sources of plasmids have been previously
described [21].
2.2. Total Internal Reflection Fluorescent Microscopy (TIRFM)
Neuro-2a cells were cultured in glass-bottom poly-d-lysine-coated imaging dishes (MatTek
Corporation, Ashland MA). Forty-eight hours after nAChR transfection, the culture dishes
were transferred to a stage-mounted dish incubator (37°C) (Warner Instruments, Hamden
CT) on an inverted microscope (IX71; Olympus). The microscope was equipped with an
Olympus Plan Apo 100 × 1.45 numerical aperture oil objective and a Mitutoyo micrometer
to control the position of the fiber optic and TIRF evanescent field illumination. TIRFM
visualizes fluorescently labeled molecules within ~200 nm above the glass dish. Such
molecules include those expressed in the cell membrane and in near-membrane intracellular
structures [24–26]. eGFP fluorophores were excited with a 488-nm air-cooled argon laser,
and an Optosplit II image splitter (Cairn Research, Faversham UK) was used to
simultaneously detect fluorescence emission from eGFP and pCS2-mCherry, a plasma
membrane (PM) marker.
Images were captured with an iXON DU-897, back-illuminated EM-CCD camera. Sample
exposure rate, percent laser transmission, and gain parameters were initially adjusted, then
maintained constant across all samples for each imaging session. 488-nm laser lines were
linearly s-polarized as revealed using an achromatic 400 – 800-nm half-wave plate
(AQWP05M-600; Thorlabs, Newton NJ).
The methodology for quantification of TIRFM images is described in detail elsewhere [21].
In brief, α6-eGFP served as a subcellular marker for nAChR localization. To obtain ER
regions of interest (ROIs), average PM fluorescence intensity and background signal was
subtracted from the entire TIRF image. PM fluorescence was extracted as follows: Raw
TIRF images were converted to background-subtracted images and the ER fluorescence was
thresholded and selected. ER fluorescence was then subtracted from the original image to
generate images with PM fluorescence signals. These procedures yielded a dataset of several
hundred thousand pixel intensities over 15 – 50 cells in each experimental group. Integrated
densities are simply the sum of pixel values for either PM or ER or ER + PM (using whole
TIRF footprint images). Mean pixel-based PM integrated densities were derived: dividing
the total integrated density of all pixels of imaged cells from each experimental group by the
number of imaged cells, and were used as pixel-based measure of the mean population of
PM localized receptors. Ratios of integrated densities for whole TIRF footprint (ER + PM)
to ER were used to determine the post-Golgi fraction of receptors. For PM integrated density
measurements, rather than plotting SEMs (which would be indistinguishably small on the
plots), we have used “error bars” to depict 99% confidence intervals based on a two-tailed t -
test.
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2.3. Spectral Confocal microscopy
A spectrally resolved laser-scanning confocal microscope (Eclipse C1si, Nikon) was
equipped with a 63 × 1.4 numerical aperture VC Plan Apo oil objective. Before imaging,
cell culture medium was replaced with phenol red-free CO2-independent Leibovitz L-15
medium. All images were taken from live cells 48 h after transfection at 37°C. Cellular
eGFP and mCherry fluorescence signals were acquired after sequential excitation with 488-
nm (for eGFP) and 561-nm (for mCherry) lasers. Full-emission spectra were acquired in 5-
nm bins between 500 and 660 nm, and the signal of each expressed fluorophore was linearly
unmixed from the raw spectral image using reference spectra from control cells expressing
only eGFP or only mCherry fusion constructs.
2.4. Patch clamp recordings
Recorded cells were visualized with an upright microscope (BX50WI; Olympus) in either
bright field or fluorescence (eGFP and mCherry) mode. Electrophysiological signals were
recorded with a MultiClamp 700B amplifier (Molecular Devices, Union City, CA), Digidata
1322 analog-to-digital converter (Axon Instruments), and pClamp 9.2 software (Axon
Instruments). Patch pipettes were filled with solution containing (in mM): 135 K gluconate,
5 KCl, 5 EGTA, 0.5 CaCl2, 10 HEPES, 2 Mg-ATP, and 0.1 GTP (pH was adjusted to 7.2
with Tris-base, and osmolarity was adjusted to 280 – 300 mOsm with sucrose). The
resistance of patch pipettes was 4 – 6 MΩ for whole-cell recordings, and 12–15 MΩ for
outside-out patch single-channel recordings. Junction potential was nulled just before
forming a gigaseal. Series resistance was monitored without compensation throughout the
experiment (Multiclamp 700B). The data were discarded if the series resistance (10 – 25
MΩ.) changed by more than 20% during recordings. All recordings were done at room
temperature.
Data were sampled at 10 kHz and filtered at 2 kHz for whole-cell recordings, and sampled at
20 kHz and filtered at 4 kHz for single-channel recordings. Nicotinic agonists were
dissolved in extracellular solution containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2,
10 HEPES, and 10 glucose (320 mOsm, pH set to 7.3 with Tris-base), and were puffed (0.1
or 3 s, 20 psi) onto voltage-clamped Neuro-2a cells (holding potential (VH), −65 mV), or
outside-out patches (VH, −65 or −60 mV). To avoid receptor desensitization by repetitive
ACh application, we applied ACh at ~3 min intervals, and continually perfused the
recording chamber with extracellular solution [27–28].
2.5. Chemicals and applications
Mouse neuroblastoma 2a (Neuro-2a; CCL-131) cells were obtained from ATCC (Manassas,
VA). pcDNA3.1(+) expression vectors and fetal bovine serum were purchased from
Invitrogen (Carlsbad, CA). Expressfect was purchased from Denville Scientific (South
Plainfield, NJ). Acetylcholine chloride (ACh), dihydro-β-erythroidine hydrobromide
(DHβE), and (−)-nicotine hydrogen tartrate salt (nicotine) were from Sigma-Aldrich (St.
Louis, MO). TC-2403 was provided by Targacept Inc. (Winston-Salem, NC).
2.6. Data analysis
Clampfit 9.2 was used to analyze both whole-cell and single-channel currents. For whole-
cell currents, we low-pass filtered traces at 1 kHz, measured peak amplitude, and estimated
decay time constant by fitting 10 – 90% of decay with one or two exponential terms. A Chi-
square test was used to compare incidences of α6β2 nAChR current among cells with
different transfections (α6-eGFPβ2-wt, α6-eGFPβ2-DM, and α6-eGFPβ2-DM plus Sec24D-
mCherry). The difference of decay time constant between groups of cells was assayed by
one-way ANOVA. When drug effects were tested, the amplitude of ACh-induced currents
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during the application of antagonists or 1 μM nicotine was normalized to its mean value
observed during control period (average of 3 responses). Drug effects were expressed as %
inhibition (mean ± SEM), while the recovery after drug washout was expressed as % of
control values. The statistical significance of drug effects was assessed by a paired two-
tailed t-test.
In outside-out patch recordings, we selected single-channel events that occurred within 5 s
after ACh puffs (Fig. 6A1, B1). This time window matches the decay of whole-cell currents
(Fig. 1, 4). We low-pass filtered signals at 4 kHz by Gaussian or Butterworth-8-pole filters,
and used the event detection feature (single-channel search) in Clampfit to detect channel
openings that were longer than 0.1 ms (Fig. 6A2, B2). We pooled all events from cells
transfected with either α6-GFPβ2-DM or α4-GFPβ2 nAChRs, and plotted histograms for
both amplitude (0.1 pA per bin) and dwell time (0.2 ms per bin) of one-level openings (Fig.
6). The mean of each parameter was estimated after curve fitting. The amplitude distribution
was fitted by a Gaussian relation, and the distribution of open times was fitted to a single
exponential relation. We performed a two-tailed t-test to compare single-channel
conductance, and used the Kolmogorov-Smirnov test to compare open time between α6-
GFPβ2-DM and α4-GFPβ2-wt nAChRs.
Values of p < 0.05 were considered significant.
3. Results
3.1. ACh-induced currents in Neuro-2a cells transfected with α6-eGFPβ2-wt and α4-
eGFPβ2-wt nAChRs
In order to visualize α6β2 nAChRs, we transfected Neuro-2a cells with α6-eGFP and β2-wt
nAChR subunits. Forty-eight hours after transfection, most eGFP-positive cells showed
cytoplasmic localization of eGFP aggregates. In a small fraction of cells, eGFP was evenly
expressed in cytoplasm and periphery (Fig. 3A). Since peripheral receptors may include
those inserted in PM, which could respond to agonist, we selected cells that evenly
expressed –6-eGFP in cytoplasm and periphery (Fig. 3 A) for patch clamp recording. We
recorded inward currents in 26% (5 / 19) of cells in response to puffed ACh (300 μM, 0.1 s,
20 psi) (Fig. 1A1). Using the same methods, we transfected α4-eGFP plus β2-wt subunits
into Neuro-2a cells [21]. Forty-eight hours after transfection, we detected ACh-induced
inward currents from all recorded α4-eGFP-positive cells (Fig. 1A2–3).
300 μM ACh-induced inward currents in α6-eGFPβ2-wt cells (54 ± 10 pA, n = 5, Fig. 1A1,
B) were much smaller than those in α4-eGFPβ2-wt cells (690 ± 140 pA, n = 9, Fig. 1A3, B).
Although 3 μM ACh induced no current in α6-eGFPβ2-wt cells that responded to 300 μM
ACh (n = 2, data not shown), it evoked inward currents (73 ± 12 pA, n = 9, Fig. 1A2, B) in
cells transfected with α4-eGFPβ2-wt nAChRs. The averaged decay time constant of 300 μM
ACh-induced α6-eGFPβ2-wt currents was 333 ± 67 ms (n = 5), while that of 3 and 300 μM
ACh-induced α4-eGFPβ2-wt currents was respectively 932 ± 69 ms (n = 9) and 1686 ± 120
ms (n = 9) (Fig. 1C).
All known nAChRs are at least 50% activated by 300 μM ACh used in the experiment of
Fig. 1 [29–30]. α6β2 nAChRs are not exceptional in this regard [20]. Therefore, it is
unlikely that the small size of the observed ACh-induced α6-eGFPβ2-wt currents arose from
the activation of a small fraction of functional receptors, although we have not gathered
systematic dose-response data. It seemed more appropriate to pursue the hypothesis that a
large majority of α6-eGFPβ2-wt nAChRs do not insert into the PM. This supposition
motivated the experiments described below.
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3.2. β2 subunits with enhanced ER export mutations increased membrane insertion of α6-
eGFPβ2 nAChRs
The mouse β2 subunit has an ER retention / retrieval motif (365RRQR368), but lacks an ER
export motif (347LFL349, instead of 347LFM349) [21]. We previously measured the effects
of disrupting the ER retention motif (365AAQA368) and reconstituting ER export motif
(347LFM349) in the β2 subunit; the doubly mutant β2 subunit is called β2-DM or
β2enhanced-ER-export. Incorporation of α2-DM increases the number of ERES [21] and
subsequently facilitates PM insertion of α4-eGFPβ2 nAChRs. We were encouraged to
conduct analogous experiments with α6 subunits, because the β4 subunit possesses an ER
export motif and lacks an ER retention / retrieval motif [21]; and both α4β4 and α6β4
nAChRs show much more functional expression than the corresponding α4β2 and α6β2
heteropentamers [15, 21]. Therefore, we hypothesized that these mutants could enhance
membrane insertion of α6-eGFPβ2 nAChRs.
TIRF microscopy enables visualization of fluorophores within ~200 nm of PM [24–26]. Our
studies showed that TIRFM detects fluorescent protein-tagged nAChRs localized in the PM
and peripheral ER [14, 21]. In TIRF footprints, ER is characterized by reticulate labeling,
while PM shows uniform fluorescence. Subcellular differences in fluorescence labeling
became apparent in PM and ER subtracted TIRF images (Fig. 2A). We consistently
observed that ER was 2 to 3 folds brighter than PM. We exploited subcellular differences in
morphology and fluorescence intensity to separately demarcate and quantify PM and ER
fluorescence (Fig. 2A, see Methods).
To confirm our hypotheses, we used TIRFM to compare PM localization of α6-eGFPβ2-wt
and α6-eGFPβ2-DM nAChRs. The average pixel-based measure of PM integrated density
for α6-eGFPβ2-DM receptors was ~2 folds greater than that of α6-eGFPβ2-wt nAChRs (Fig.
2B). We utilized ratios of whole cell footprint to ER integrated density to quantify ER-
associated changes in receptor localization. The ratio for α6-eGFPβ2-DM nAChRs (~1.2)
was only slightly higher than that for α6-eGFPβ2-wt nAChRs in Neuro-2a cells (Fig. 2C),
while it is substantially lower than the corresponding parameter for α4β2 nAChRs (3 – 4)
and α4β2-DM nAChRs (7 – 9) [21].
To enhance our chances of detecting functional α6-eGFPβ2 nAChRs, we performed
electrophysiological recordings in Neuro-2a cells transiently expressing α6-eGFPβ2-DM
nAChRs. As expected, 300 μM ACh evoked inward currents in a significantly larger
proportion of α6-eGFPβ2-DM cells (28 out of 51) than in α6-eGFPβ2-wt cells (5 out of 19)
(p = 0.03) (Fig. 3C).
These results only partially confirm the hypothesis that the β2-DM subunits could enhance
ER export and, eventually, PM insertion of α6-eGFPβ2 nAChRs. Most α6β2-DM nAChRs
remained trapped in the ER, although the ER exit rate was apparently great enough to
produce an increased fraction of cells with functional PM nAChRs.
3.3. Visualization of a fluorescently tagged ERES marker
We continued to pursue the hypothesis that ER trapping dominates the poor surface
expression of α6β2 nAChRs. We transfected Neuro-2a cells with α6-eGFPβ2-DM, and
Sec24D-mCherry, a fluorescently-tagged ERES marker, as well. When we chose cells with
moderate to high density of α6-eGFP (Fig. 3B1), and abundant, large and bright ERES (Fig.
3B2), we detected inward currents (300 μM ACh) in 86% (24 / 28) of cells (Fig. 3C).
Therefore, choosing cells with more ERES dramatically increased our chances of detecting
functional α6-eGFPβ2-DM nAChRs. The rather small number of cells displaying α6-
eGFPβ2-wt nAChR currents vitiated systematic study of these responses. However Fig. 3D
conveys the impression that, compared with α6-eGFPβ2-wt nAChR currents, the distribution
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of α6-eGFPβ2-DM nAChR currents in cells co-transfected with or without Sec24D-mCherry
was similar at the two lower quartiles (<50%), but larger at the highest quartile (> 75%). The
average responses for the three groups were similar within 25% (α6-eGFPβ2-DM: 70 ± 11
pA, n = 28; α6-eGFPβ2-DM plus Sec24D-mCherry: 66 ± 10 pA, n = 24; α6-eGFPβ2-wt: 54
± 10 pA, n = 5). The increased incidence of α6-eGFPβ2 nAChR currents suggested that
introducing β2-DM increased membrane insertion of α6-eGFPβ2 nAChRs, while the ERES
marker could facilitate choosing cells expressing functional receptors. We do not know
whether the effects of the fluorescent Sec24D arise solely from our ability to visualize cells
with increased ERES, or also from the increased COPII levels in those cells.
Lack of difference in response waveforms among α6-eGFPβ2-wt, α6-eGFPβ2-DM, and α6-
eGFPβ2-DM plus Sec24D-mCherry cells (Fig. 3E) suggested that neither β2-DM nor
Sec24D-mCherry altered the intrinsic functional properties of α6β2 nAChRs. The
observations gave us the confidence to conduct electrophysiological and pharmacological
studies of the expressed α6β2 nAChRs.
3.4. Pharmacological properties of heterologously expressed α6β2 nAChRs in Neuro-2a
cells
We observed that both nicotine and TC-2403 activated inward currents in cells expressing
functional α6-eGFPβ2-DM nAChRs (Fig. 4A, B). This is consistent with a previous study
showing that nicotine and TC-2403 stimulate both dopamine release and locomotion in
α6L9'S transgenic mice [3].
Next we tested whether functional α6-eGFPβ2-wt / α6-eGFPβ2-DM nAChRs could be
blocked by either α6* or β2* nAChR antagonists. In this set of experiments, antagonists
were added in the perfusate at the intended concentration, until stable effects were obtained.
Indeed, the α6β2 currents were blocked by 80 nM α-conotoxin MII, an antagonist of α3*
and α6* nAChRs (Fig. 4C1–2). The currents recovered to 70 ± 8% (n = 5, p = 0.01) of initial
values after 20 min washout. DHβE (300 nM), a selective antagonist for β2* nAChRs,
blocked 300 μM ACh-induced α4-eGFPβ2 nAChR currents (by 97 ± 1%, n = 3, p =
0.00001, data not shown), and the currents recovered to about 50% of baseline values after
15 min washout (data not shown). However, α6-eGFPβ2-DM nAChRs showed lower
sensitivity to DHβE, along with faster and greater recovery (Fig. 4D1–2). In particular, 300
nM and 2 μM DHβE inhibited α6-eGFPβ2-DM nAChR currents by 39 ± 3% (n = 4, p =
0.0005) and 59 ± 9% (n = 4, p = 0.003), respectively, while the currents recovered to 90 ±
5% (n = 5) of initial currents following 10 min washout of 2 μM DHβE. These data suggest
that α6β2 nAChRs might have lower affinity to DHβE than α4β2 nAChRs.
We found that removing extracellular Ca2+ by replacing 2 mM Ca2+ with 2 mM Mg2+ (0
Ca2+) significantly decreased α4-eGFPβ2-wt nAChR currents by 30 ± 7% (n = 4, p = 0.008,
Fig. 4E2). A similar phenomenon was observed in α6-eGFPβ2-DM nAChRs (Fig. 4E1). In 0
Ca2+ medium, 300 μM ACh-induced currents diminished by 30 ± 3% (n = 4, p = 0.00004,
Fig. 4E2). These data on Ca2+ modulation of α6β2 nAChRs resemble results with other
nAChR subunit combinations [31–32].
3.5. Desensitization of α6-eGFPβ2-DM nAChRs
Desensitization is a common property of nAChRs. The ACh puffs (0.1 s) used to evoke α6-
eGFPβ2-DM nAChR currents were one order of magnitude briefer than the decay time
constant of the currents (Fig. 1, Fig. 4). The current decay could be a consequence of either
agonist diffusion, deactivation of receptors due to agonist dissociation, receptor
desensitization, or a combination of these processes. To isolate the role of desensitization in
response waveforms, we puffed 300 μM ACh for 3 s (Fig. 5A1). The α6-eGFPβ2-DM
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nAChR current decay was described successfully by a two-exponential function (see in
Methods). The faster (τ = 283 ± 24 ms, n = 7) and slower component (τ = 3528 ± 349 ms, n
= 7) respectively account for 66 ± 5% (n = 7) and 23 ± 4% (n = 7) of peak amplitude.
Next we examined α6-eGFPβ2-DM nAChR desensitization by 1μM nicotine. We puffed
300 μM ACh (0.1 s) onto Neuro-2a cells to induce α6-eGFPβ2-DM nAChR currents at 3
min intervals. After a stable baseline response was established (~10 min), we added 1 μM
nicotine into the perfusate, and found that ACh-induced currents diminished to nearly zero
within a few min (Fig. 5B1–2). The currents recovered to 58 ± 3% of initial values (n = 3)
after 6 min washout, and reached 88 ± 2% (n = 3) of initial values after 20 min washout.
3.6. Single-channel analysis of α6β2 and α4β2 nAChR currents in Neuro-2a cells
To characterize the function of α6β2 nAChRs at the single-channel level, and to compare
with α4β2 nAChR function, we performed outside-out patch single-channel recordings from
cells that displayed 300 μM ACh-induced inward currents in whole-cell mode. As illustrated
in Fig. 6A1, 300 μM ACh (0.1 s)-induced events show 1 – 2 opening levels in voltage-
clamped patches (VH, −60 mV) from the cells transfected with α6-eGFPβ2-DM nAChRs.
However, 300 μM ACh evoked 20 – 40 pA currents in voltage-clamped patches (VH, − 65
mV) from the cells transfected with α4-eGFPβ2 nAChRs (data not shown). We decreased
ACh concentration to 3 μM to limit the number of α4-eGFPβ2 nAChRs being activated.
This strategy provided us with unambiguous single-channel events for further analysis. As
illustrated in Fig. 6B1, 3 μM ACh evoked ≤ 3 levels of channel openings. In both α6-
eGFPβ2-DM and α4-eGFPβ2 patches, we observed that ACh produced channel opening
over a time course of ~5 s, (Fig. 6A1, B1), similar to the waveform of whole-cell responses
to ACh puffs (Fig. 1, 4). Fig. 6A2 and B2 show expanded traces of single level openings. We
pooled single level opening events from 10 α6-eGFPβ2-DM patches and 7 α4-eGFPβ2-wt
patches. The single-channel conductance of α6-eGFPβ2-DM nAChRs (24 pS) was similar to
that of α4-eGFPβ2-wt nAChRs (26.2 pS) (p = 0.35, two tailed t-test) (Fig. 6A3, B3). The
single-channel open time of α6-eGFPβ2-DM nAChRs (τ = 1.4 ms, n = 279) was
significantly longer than that of α4-eGFPβ2-wt nAChRs (τ = 0.6 ms, n = 875) (p < 0.0001,
Kolmogorov-Smirnov test) (Fig. 6A4, B4).
4. Discussion
4.1. Increasing the membrane expression of α6β2 nAChRs by enhancing ER export
After transfecting Neuro-2a cells with α6-eGFPβ2 nAChRs, we selected cells with uniform
expression of α6-eGFP in cytoplasm and periphery (Fig. 3A), presumably indicating surface
expression. This provided a modest success rate (26%, Fig. 1A1, 3C), higher than previous
studies [14, 18, 20], which showed zero to 15%. When we replaced β2-wt with β2-DM
subunits, we observed 1) that PM insertion of α6-eGFP was increased by 2 fold (Fig. 2B), 2)
that functional α6β2 nAChRs were detected in more than half of transfected cells (Fig. 3C),
and 3) that ACh induced larger currents in some transfected cells (Fig. 3D).
To achieve even greater success rates, we also fluorescently tagged Sec24D molecules.
Following assembly, nAChRs bind to Sec24D through LFM motifs in M3-M4 loop,
resulting in the formation of specialized ERES [21, 33–34]. ERES number increases in
direct proportion to nAChR export rate [21]. Therefore, cells having more ERES could more
efficiently export nAChRs to PM. Indeed, 86% of cells with abundant, bright, and large
ERES (Fig. 3B2), displayed functional α6-eGFPβ2-DM nAChRs (Fig. 3C). Although
current amplitude in the selected cells was modestly (22%) larger than that in cells
transfected with α6-eGFPβ2-wt nAChRs, it was similar to that in cells transfected with α6-
eGFPβ2-DM nAChRs (Fig. 3D). Apparently ACh responses occur in α6-eGFPβ2-DM cells
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with abundant and large ERES; and the ERES marker enabled the visualization of α6-
eGFPβ2-DM cells expressing functional receptors.
4.2. Pharmacology of α6β2 nAChRs
In this study, α6β2 nAChRs were activated by ACh, nicotine (Fig. 4A), and TC-2403 (Fig.
4B), consistent with a previous study using α6L9'S transgenic mice [3], although another
study found that TC-2403 has no detectable agonist activity at α6β2* nAChRs [9]. The α6-
eGFPβ2-DM nAChRs were blocked by α-conotoxin MII, recovering after 20 min washout
(Fig. 4C1–2). This recovery is not directly comparable with the slower recovery shown in
previous studies using native systems, including brain slices and synaptosomes [3, 8, 28]. It
is possible that α6* nAChR subtypes (e.g. those containing β3 and/or α4 subunits) could
have different dissociation rates for α-conotoxin MII. Interestingly, α6β2 nAChRs were
partially and reversibly blocked by DHβE (Fig. 4D1–2), contrasting with the fact that α4β2
nAChRs are blocked by DHβE at low hundreds nM.
We also observed that at levels achieved during smoking, nicotine desensitized α6β2
nAChRs (Fig. 5B1–2). The effect is roughly as robust as previous studies on α4β2 nAChRs
[35–36]. However, when nicotine was washed out, α6β2 nAChR currents recovered more
rapidly and thoroughly than α4β2 nAChR currents [35]. These data suggested 1) that the
desensitized state(s) of α6β2 nAChRs might have lower affinity to nicotine than α4β2
nAChRs; 2) that α6β2 nAChRs would regain function more readily than α4β2 nAChRs if
desensitized.
Extracellular Ca2+ allosterically modulates nAChRs, and increases channel opening
probability [31–32]. In the brain, high levels of neuronal activity deplete extracellular Ca2+,
and this could lower opening probability of nAChRs [37–38]. We observed that removal of
extracellular Ca2+ decreased both α4β2 and α6β2 nAChR currents to roughly the same
extent (Fig. 4E), suggesting that α6β2 nAChRs could also be modulated by neuronal activity
in vivo.
Our pharmacological data thus indicate that α6β2 nAChRs could be distinguished from α4β2
nAChRs by their resistance to DHβE and rapid recovery from nicotine desensitization. In
some situations, desensitization could be physiologically relevant by changing the balance
of excitation and inhibition in neural circuits [39–40].
4.3. Electrophysiological characterization of α6β2 nAChRs
We observed that the decay of α6-eGFPβ2-DM nAChR currents, evoked by 3 s puff of 300
μM ACh, was described by a two-exponential function (Fig. 5A1–2). This suggested either
that multiple processes account for “desensitization” of individual α6β2 nAChRs, or that
more than one population of α6β2 nAChRs exist, with different desensitization rates (Fig.
5A2). By analogy with α4β2 nAChRs (see next paragraph), it would not be surprising to find
that these two components could reflect different receptor stoichiometries: (α6)3(β2)2 and
(α6)2(β2)3. Further investigations would test this hypothesis by performing 1) Förster
resonance energy transfer [21–22], 2) biased transfections of α6 and β2 subunits with
different ratios to assess changes in the predominance of faster and slower components [41–
42], and 3) systematic dose-response studies [41–43]. Additionally, the physiological
significance of these two components also warrants further investigations.
α4β2 nAChRs assemble into two stoichiometries: (α4)3(β2)2 and (α4)2(β2)3 [21–22, 41–44].
Low concentrations (< 10 μM) of ACh primarily activate high sensitivity α4β2 nAChRs,
while high concentrations (≥ 100 μM) of ACh activate both. Previous studies revealed that
high sensitivity α4β2 nAChRs have smaller single-channel conductance (17 – 31 pS) than
low sensitivity receptors (44 – 46 pS) [32, 43–48]. In this study, we activated α4β2 nAChRs
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on voltage-clamped outside-out patches by 3 μM ACh (Fig. 6B1). Given this concentration
and the single-channel conductance of 26.2 pS (Fig. 6B2), we suggest that most of the α4β2
single-channel events were mediated by high sensitivity receptors.
A previous study reported that the EC50 of ACh for α6β2 nAChRs is 150 μM [20].
Therefore, 300 μM ACh can activate both high and low sensitivity α6β2 nAChRs if any. We
observed a single conductance component in 300 μM ACh-induced single α6β2 nAChR
currents (Fig. 6A2–3). It could be 1) that, in our transfection condition, the majority of α6β2
nAChRs assembled in one stoichiometry, and the number of recorded events were too low to
show a minority component, or 2) that α6β2 nAChRs in two stoichiometries could have the
same single-channel conductance or even a single sensitivity component as previously
reported [20]. The average conductance of α6β2 nAChRs was 24 pS, which was similar to
that of α4β2 nAChRs (26.2 pS) (Fig. 6A3, B3). The single-channel duration of α6β2
nAChRs was significantly longer than that of α4β2 nAChRs. We applied 3 μM ACh to
activate α4β2 nAChR single-channel events, but applied 300 μM ACh to activate α6β2
nAChR single channel events, and still observed that α4β2 nAChRs opened more frequently
(875 events / 25.3 s) than α6β2 nAChRs (279 events / 50 s). The low open probability of
α6β2 nAChRs could result from the high concentration of ACh, which could cause receptor
desensitization.
4.4. Additional subunits and stoichiometries?
Note that native α6* nAChRs include several subunit combinations and stoichiometries. The
α6β2 nAChRs studied here may be the subtype with the least sensitivity to agonists, the
lowest binding affinity to α-conotoxin MII and DHβE, and the least biological relevance.
The α6α4β2* nAChRs could be the major physiologically relevant subtypes for dopamine
release [2]. Including α4 and/or β3 subunits in α6β2* nAChRs increases receptor sensitivity
[7–8], and including β3 subunits also increases expression levels [15–17, 19].
Thus we can hope that the present techniques for expressing purely α6β2 nAChRs (β2-DM
subunits, fluorescently tagged α6 subunits, and ERES markers) may have overcome the
greatest hurdle. However, we do not yet know whether one or more of the strategies
introduced here could also increase chances of detecting functional α4α6β2 and α4α6β2β3
nAChRs in Neuro-2a cells. If so, these systems could be used to investigate pharmacological
and electrophysiological properties of α6* nAChRs subtypes, and may facilitate drug
screening for both Parkinson's disease protection and smoking cessation.
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Figure 1.
α6β2 and α4β2 nAChR currents in transfected Neuro-2a cells. (A1–3) Representative traces
showing 300 μM ACh-induced current in an α6-eGFPβ2-wt cell (A1), and 3 μM (A2) and
300 μM (A3) ACh-induced currents in an α4-eGFPβ2-wt cell. Arrows indicate 100 ms ACh
puffs. Summaries of peak amplitude and decay time constants, respectively, are shown in
(B) and (C). Transfected nAChR subunits are indicated on the x-axis. α6β2: α6-eGFPβ2-wt.
α4β2: α4-eGFPβ2-wt. ACh concentrations are indicated above each vertical bar (Mean ±
SEM). Cell numbers are shown in parentheses.
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Figure 2.
The β2-DM subunit (also called β2enhanced-ER-export) increased fluorescent α6β2 nAChR
density in the PM. (A) Representative TIRFM footprint of a Neuro-2a cell expressing α6-
eGFPβ2-wt. The TIRF footprint was processed post-acquisition to obtain plasma membrane
(PM) subtracted and ER subtracted footprint as indicated. Images are pseudo-colored using
the fire-color look up table (LUT), as shown in each panel. Scale bars, 10 μm. (B)
Quantification of averaged PM integrated density for TIRF images. Transfected subunits are
shown on x-axis. Error bars are 99% confidence interval. (C) Quantification of footprint /
ER ratios from TIRF images. Transfected subunits are indicated on x-axis. Error bars are ±
99% confidence limits. Numbers of cells are indicated in parentheses for each graph.
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Figure 3.
Improved strategies to detect functional α6β2 nAChRs in vitro. (A) Representative images
of recorded Neuro-2a cells transfected with α6-eGFPβ2-wt. Arrow: plasma membrane. Scale
bar: 10 μm. (B1–2) Representative images of a Neuro-2a cell transfected with α6-eGFPβ2-
DM plus Sec24D-mCherry, showing α6-eGFP (B1) and Sec24D-mCherry (B2). An arrow in
(B1) indicates plasma membrane, which is not well defined. Arrows in (B2) indicate ER exit
sites. Scale bar: 10 μm. (C) Incidences of ACh-induced currents in cells transfected with α6-
eGFPβ2-wt, α6-eGFPβ2-DM and α6-eGFPβ2-DM plus Sec24D-mCherry. Black square: %
of cells responding to ACh. Gray square: % of cells not responding to ACh. Cell numbers to
calculate these percentages are indicated above stacked bars. (D) Box plots of current
amplitude in cells transfected with α6-eGFPβ2-wt (n = 5), α6-eGFPβ2-DM (n = 28), or α6-
eGFPβ2-DM plus Sec24D-mCherry (n = 24). (E) Summary of decay time constant of 300
μM ACh-induced currents in cells transfected with α6-eGFPβ2-wt, α6-eGFPβ2-DM, and α6-
eGFPβ2-DM plus Sec24D-mCherry (Mean ± SEM). Cell numbers are indicated in each
vertical bar.
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Figure 4.
Pharmacology of α6β2 nAChRs in vitro. α6-eGFPβ2-DM nAChRs were activated by either
nicotine (A) or TC 2403 (B). (C1–2) Typical traces (C1) and summary (C2) showing that
α6β2 nAChR currents were blocked by 80 nM α-conotoxin MII, and recovered 20 min after
washout. (D1–2) Typical traces (D1) and summary (D2) showing that 0.3 and 2 μM DHβE
partially and reversibly inhibited α6-eGFPβ2-DM nAChR currents. (E1–2) Both α6-eGFPβ2-
DM and α4-eGFPβ2-wt nAChR currents significantly decreased after removal of
extracellular Ca2+ (0 Ca2+). Cell numbers are shown in parenthesis. Vertical bars show
Mean ± SEM. Arrows indicate ACh applications (0.1 s, 20 psi).
Xiao et al. Page 17
Biochem Pharmacol. Author manuscript; available in PMC 2012 October 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 5.
Desensitization of α6β2 nAChRs in vitro. (A1) A typical trace of 3 s ACh (300 μM) induced
α6-eGFPβ2-DM nAChR current. (A2) The current decay was fitted by two exponential
components. The faster component contributed > 70% to the peak amplitude. Cell numbers
are indicated in each panel. (B1–2) Typical traces (B1) and summarized time course (B2, n =
3) showing that α6-eGFPβ2-DM nAChRs desensitized within a few min in 1 μM nicotine,
and recovered gradually after nicotine was washed out. Arrows in B1 indicate ACh
applications (0.1 s, 20 psi).
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Figure 6.
Single-channel properties of α6β2 and α4β2 nAChRs. A typical trace (8 s) of ACh-induced
response in an outside-out patch from a Neuro-2a cell transfected with either α6-eGFPβ2-
DM (A1) or α4-eGFPβ2 (B1) nAChRs. Arrows indicate ACh applications. An inward
current before ACh application in A1 was caused by a −5 mV voltage step. Typical traces of
single level openings of α6-eGFPβ2-DM (induced by 300 μM ACh) and α4-eGFPβ2
nAChRs (induced by 3 μM ACh) are respectively shown in (A2) and (B2). Holding potential
(VH), and closed and open states are indicated. Histograms of α6-eGFPβ2-DM and α4-
eGFPβ2 nAChR single-channel event amplitude are respectively shown in (A3) and (B3).
Both were fit to a Gaussian equation (Thick black curve). Histograms of α6-eGFPβ2-DM
and α4-eGFPβ2 nAChR single-channel open-time distributions are respectively shown in
(A4) and (B4). Both were fitted to a single exponential component (Thick black curve).
Mean open time (τ) is indicated.
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